Page 1

ISOFOL MEDICAL AB ( PUBL ) INTERIM REPORT H₂N HN JANUARY SEPTEMBER 2021 SIGINIFICANT EVENTS DURING THE THIRD QUARTER ■ No significant events to report during the quarter H SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD ■ On October 21 , Isofol was listed on Nasdaq Stockholm OH OH Intense work to move the company closer to market launch Isofol is developing the cancer drug arfolitixorin Isofol is developing the drug candidate arfolitixorin to improve the efficacy of standard 5 - FU - based che motherapy for advanced colorectal cancer ( CRC ) . Arfolitixorin is currently being evaluated in the global pivotal Phase III AGENT study on patients with advanced CRC . The Group consists of the Parent Company , Isofol Medical AB ( publ ) , and the subsidiary , Isofol Medical Incentive AB . The business is conducted by the Parent Company , while the subsidiary only administers the Group's incentive programs . The descriptions of the business , results and financial position in this in terim report apply to both the Group and the Parent Company , unless otherwise stated . FINANCIAL INFORMATION Third quarter , July - September 2021 ■ Net revenue amounted to TSEK 5,154 ( 18,439 ) and other revenue to TSEK 0 ( 0 ) ■ The result for the period amounted to TSEK -51,026 ( -30,100 ) ■ Earnings per share amounted to SEK -0.32 ( -0.36 ) ■ Cash and cash equivalents at September 30 amounted to TSEK 420,861 ( 153,612 ) January - September 2021 ■ Net revenue amounted to TSEK 17,702 ( 18,439 ) and other revenue to TSEK 0 ( 0 ) ■ The result for the period amounted to TSEK -139,081 ( -134,333 ) ■ Earnings per share amounted to SEK -1.22 ( -2.48 ) KEY FIGURES TSEK Net revenue Result for the period Earnings per share ( SEK ) Cash and cash equiv alents ISOFOL 2021 Jul - Sep 5,154 -51,026 -0.32 420,861 2020 Jul - Sep 18,439 -30,100 -0.36 153,612 2021 Jan - Sep 17,702 -139,081 -1.22 420,861 2020 Jan - Sep 18,439 -134,333 -2.48 153,612 2020 Jan - Dec 37,119 -188,992 -3.07 116,393 ISOFOL | Interim report , January - September 2021 1